CN101340919B - 治疗艰难梭菌相关的腹泻的方法 - Google Patents
治疗艰难梭菌相关的腹泻的方法 Download PDFInfo
- Publication number
- CN101340919B CN101340919B CN2006800479861A CN200680047986A CN101340919B CN 101340919 B CN101340919 B CN 101340919B CN 2006800479861 A CN2006800479861 A CN 2006800479861A CN 200680047986 A CN200680047986 A CN 200680047986A CN 101340919 B CN101340919 B CN 101340919B
- Authority
- CN
- China
- Prior art keywords
- chemical compound
- formula
- mixture
- mcc
- clostridium difficile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- CBDYRNDQGQFMJL-IUCAKERBSA-N CC(C)C(O[C@@H](C1)C(C)(C)OC[C@H]1O)=O Chemical compound CC(C)C(O[C@@H](C1)C(C)(C)OC[C@H]1O)=O CBDYRNDQGQFMJL-IUCAKERBSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
MCC,50mg (n=10) | MCC,100mg (n=8) | MCC,200mg (n=11) | 万古霉素(n=7) | |
第0天 | 6.64±2.82 | 6.64±2.82 | 7.04±2.87 | 7.39±2.67 |
第10天 | 8.23±2.60 | 6.30±2.53 | 7.34±3.06 | 3.62**±1.90 |
p* | 0.11 | 0.44 | 0.56 | 0.03 |
Claims (15)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72913505P | 2005-10-21 | 2005-10-21 | |
US60/729,135 | 2005-10-21 | ||
US74964105P | 2005-12-12 | 2005-12-12 | |
US60/749,641 | 2005-12-12 | ||
PCT/US2006/041436 WO2007048059A2 (en) | 2005-10-21 | 2006-10-23 | Method of treating clostridium difficile-associated diarrhea |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011103037682A Division CN102503994A (zh) | 2005-10-21 | 2006-10-23 | 治疗艰难梭菌相关的腹泻的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101340919A CN101340919A (zh) | 2009-01-07 |
CN101340919B true CN101340919B (zh) | 2011-12-07 |
Family
ID=37963388
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011103037682A Pending CN102503994A (zh) | 2005-10-21 | 2006-10-23 | 治疗艰难梭菌相关的腹泻的方法 |
CN2006800479861A Expired - Fee Related CN101340919B (zh) | 2005-10-21 | 2006-10-23 | 治疗艰难梭菌相关的腹泻的方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011103037682A Pending CN102503994A (zh) | 2005-10-21 | 2006-10-23 | 治疗艰难梭菌相关的腹泻的方法 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1940417A4 (zh) |
JP (1) | JP2009512691A (zh) |
KR (1) | KR101399621B1 (zh) |
CN (2) | CN102503994A (zh) |
AU (1) | AU2006304868B2 (zh) |
CA (1) | CA2626698C (zh) |
HK (1) | HK1126410A1 (zh) |
WO (1) | WO2007048059A2 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7906489B2 (en) | 2004-05-14 | 2011-03-15 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
US7378508B2 (en) | 2007-01-22 | 2008-05-27 | Optimer Pharmaceuticals, Inc. | Polymorphic crystalline forms of tiacumicin B |
TWI523654B (zh) | 2007-11-27 | 2016-03-01 | 默沙東藥廠 | 抗生素巨環化合物以及其製造及使用之方法 |
JO3464B1 (ar) | 2013-01-15 | 2020-07-05 | Astellas Pharma Europe Ltd | التركيبات الخاصة بمركبات التياكوميسين |
CN104846044B (zh) * | 2014-02-17 | 2019-02-01 | 上海医药工业研究院 | 一种提高非达霉素产量的发酵培养基 |
CN105237599B (zh) * | 2015-10-09 | 2018-10-02 | 华北制药集团新药研究开发有限责任公司 | 闰年霉素a4晶体及其制备方法 |
CN107970253B (zh) * | 2017-10-25 | 2020-05-26 | 中山大学 | 台勾霉素衍生物在制备治疗寨卡病毒感染引起的相关疾病和/或症状的药物中的应用 |
CN107714713B (zh) * | 2017-10-25 | 2020-05-26 | 中山大学 | 台勾霉素衍生物在制备治疗登革病毒感染引起的相关疾病和/或症状的药物中的应用 |
US11419900B2 (en) * | 2018-06-07 | 2022-08-23 | Artugen Therapeutics Ltd. | Methods and compositions for the treatment of C. difficile |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4918174A (en) | 1986-09-26 | 1990-04-17 | Abbott Laboratories | Tiacumicin compounds |
US5583115A (en) * | 1995-05-09 | 1996-12-10 | Abbott Laboratories | Dialkyltiacumicin compounds |
AU2003251902B2 (en) * | 2002-07-29 | 2008-03-06 | Merck Sharp & Dohme Llc | Tiacumicin production |
BRPI0511119A (pt) * | 2004-05-14 | 2007-11-27 | Optimer Pharmaceuticals Inc | tratamento de doenças associadas com o uso de antibióticos |
MX340742B (es) * | 2005-01-31 | 2016-07-21 | Merck Sharp & Dohme | Compuestos macrociclicos de 18 miembros y analogos de los mismos. |
-
2006
- 2006-10-23 WO PCT/US2006/041436 patent/WO2007048059A2/en active Application Filing
- 2006-10-23 CN CN2011103037682A patent/CN102503994A/zh active Pending
- 2006-10-23 CA CA2626698A patent/CA2626698C/en not_active Expired - Fee Related
- 2006-10-23 CN CN2006800479861A patent/CN101340919B/zh not_active Expired - Fee Related
- 2006-10-23 AU AU2006304868A patent/AU2006304868B2/en not_active Ceased
- 2006-10-23 KR KR1020087012193A patent/KR101399621B1/ko active IP Right Grant
- 2006-10-23 EP EP06826544A patent/EP1940417A4/en not_active Withdrawn
- 2006-10-23 JP JP2008536608A patent/JP2009512691A/ja active Pending
-
2009
- 2009-06-10 HK HK09105230.0A patent/HK1126410A1/xx not_active IP Right Cessation
Non-Patent Citations (3)
Title |
---|
B.cavalleri ,A. Arnone,E.Di Modugno,etal.structure and biological activity of lipiarmycin B.the journal of antibiotics.1988,41(3),308-315. |
B.cavalleri,A. Arnone,E.Di Modugno,etal.structure and biological activity of lipiarmycin B.the journal of antibiotics.1988,41(3),308-315. * |
SWANSON,R,N.etal.in vitro and in vivo evaluation of tiacumicins B and C against clostridium difficile.Antimicrobial Agents and Chemotherapy.1991,35(6),Page1108-1111. * |
Also Published As
Publication number | Publication date |
---|---|
CN101340919A (zh) | 2009-01-07 |
KR20080064177A (ko) | 2008-07-08 |
WO2007048059A2 (en) | 2007-04-26 |
EP1940417A4 (en) | 2010-07-07 |
JP2009512691A (ja) | 2009-03-26 |
CA2626698C (en) | 2015-12-01 |
CN102503994A (zh) | 2012-06-20 |
EP1940417A2 (en) | 2008-07-09 |
WO2007048059A3 (en) | 2007-05-31 |
KR101399621B1 (ko) | 2014-06-18 |
AU2006304868B2 (en) | 2013-02-21 |
AU2006304868A1 (en) | 2007-04-26 |
HK1126410A1 (en) | 2009-09-04 |
CA2626698A1 (en) | 2007-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101340919B (zh) | 治疗艰难梭菌相关的腹泻的方法 | |
Jarrad et al. | Clostridium difficile drug pipeline: challenges in discovery and development of new agents | |
Nguyen et al. | The lung mycobiome: an emerging field of the human respiratory microbiome | |
US20140107054A1 (en) | Method of treating clostridium difficile-associated diarrhea | |
Mao et al. | Protective effects of natural and partially degraded konjac glucomannan on Bifidobacteria against antibiotic damage | |
Martins et al. | Plants used in folk medicine: The potential of their hydromethanolic extracts against Candida species | |
CN105753936B (zh) | 一种Rakicidins类化合物Rakicidin B1及其制备方法 | |
Xu et al. | Effects of broad-spectrum antibiotics on the metabolism and pharmacokinetics of ginsenoside Rb1: a study on rats׳ gut microflora influenced by lincomycin | |
Aldrich et al. | Discovery of anticancer agents of diverse natural origin | |
Car et al. | Mannosylated N‐aryl substituted 3‐hydroxypyridine‐4‐ones: Synthesis, hemagglutination inhibitory properties, and molecular modeling | |
Palmieri et al. | Inhibitory effect of ursodeoxycholic acid on Clostridium difficile germination is insufficient to prevent colitis: a study in hamsters and humans | |
Kaur et al. | Repurposing of FDA approved drugs against uropathogenic Escherichia coli: In silico, in vitro, and in vivo analysis | |
Wang et al. | Insight into the mechanism of Xiao–Chai–Hu–Tang alleviates irinotecan-induced diarrhea based on regulating the gut microbiota and inhibiting Gut β-GUS | |
Zhi et al. | Siderophore-mediated zinc acquisition enhances enterobacterial colonization of the inflamed gut | |
Boyanova et al. | Characteristics and trends in macrolide resistance among Helicobacter pylori strains isolated in Bulgaria over four years | |
Khadagwanshi et al. | Effect of Phaseolus vulgaris on E. coli induced peritonitis and bacteraemia in mice | |
Handayani et al. | Holothurin compound from sea cucumber (Holothuria sp.) as antifungal alternative against Candida infections | |
CN109111422A (zh) | 大环内酯类化合物及其在制备防治植物病原性致病菌药物中的应用 | |
Phan | Poop! There it is! Anti-Germinants and Biological Variables as Modulators of Clostridioides Difficile Infection (CDI) | |
Tauber et al. | In vitro inhibitory evaluation of novel amine and amide compounds against the post-translational modifier enzyme, ARTD8. | |
Sharaf et al. | Current research in microbial sciences | |
Bernabè et al. | Insoluble polysaccharides produced in plant cell cultures protect from Clostridioides difficile colitis | |
Jaber | Metabolomic profiling of antibiofilm compounds from fungal endophytes derived from Scottish seaweeds | |
Alqahtani | Antibacterial Compounds from Bacteria Isolated from Hot Springs Water in Saudi Arabia | |
Lin et al. | Effect and mechanism of Qingre Huashi decoction on drug-resistant Helicobacter pylori |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1126410 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1126410 Country of ref document: HK |
|
C56 | Change in the name or address of the patentee |
Owner name: HAODING BIOTECHCX INC. Free format text: FORMER NAME: OPTIMER PHARMACEUTICALS INC. |
|
CP01 | Change in the name or title of a patent holder |
Address after: California, USA Patentee after: Optimer Pharmaceuticals Inc. Address before: California, USA Patentee before: Optimer Pharmaceuticals, Inc. |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: Hayden Avenue, Lexington, Massachusetts, 65, 02421 Patentee after: Optimer Pharmaceuticals Inc. Address before: California, USA Patentee before: Optimer Pharmaceuticals Inc. |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: Hayden Avenue, Lexington, Massachusetts, US No. 65 02421 Patentee after: Hao Ding biotech Co.,Ltd. Address before: Hayden Avenue, Lexington, Massachusetts, US No. 65 02421 Patentee before: Optimer Pharmaceuticals Inc. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20151218 Address after: New jersey, USA Patentee after: Optimer Biotechnology Inc. Address before: Hayden Avenue, Lexington, Massachusetts, US No. 65 02421 Patentee before: Hao Ding biotech Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111207 Termination date: 20161023 |